Phase II study of nab‐paclitaxel + carboplatin for patients with non‐small‐cell lung cancer and interstitial lung disease-Reference-Cited by-同舟云学术

Phase II study of nab‐paclitaxel + carboplatin for patients with non‐small‐cell lung cancer and interstitial lung disease

Published:2019-11-06 Issue:12 Volume:110 Page:3738-3745
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Kenmotsu Hirotsugu¹^ORCID,Yoh Kiyotaka²,Mori Keita³,Ono Akira¹,Baba Tomohisa⁴,Fujiwara Yutaka⁵^ORCID,Yamaguchi Ou⁶,Ko Ryo⁷,Okamoto Hiroaki⁸,Yamamoto Nobuyuki⁹,Ninomiya Takashi¹⁰,Ogura Takashi⁴,Kato Terufumi¹¹

Affiliation:

1. Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan

2. Department of Thoracic Oncology National Cancer Center Hospital East Kashiwa Japan

3. Clinical Trial Coordination Office Shizuoka Cancer Center Shizuoka Japan

4. Department of Respiratory Medicine Kanagawa Cardiovascular and Respiratory Center Yokohama Japan

5. Department of Thoracic Oncology National Cancer Center Hospital Tokyo Japan

6. Department of Respiratory Medicine Saitama Medical University International Medical Center Saitama Japan

7. Department of Respiratory Medicine Juntendo University Graduate School of Medicine Tokyo Japan

8. Department of Respiratory Medicine and Medical Oncology Yokohama Municipal Citizen’s Hospital Yokohama Japan

9. Third Department of Internal Medicine Wakayama Medical University Wakayama Japan

10. Department of Respiratory Medicine and Allergy Okayama University Hospital Okayama Japan

11. Division of Thoracic Oncology Kanagawa Cancer Center Yokohama Japan

Funder

Ministry of Health, Labour and Welfare

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14217

Reference29 articles.

1. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

2. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

3. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

4. Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer

5. Interstitial lung disease associated with drug therapy

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy;Scientific Reports;2024-05-03

2. Japanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition;Respiratory Investigation;2024-05

3. Atezolizumab and nintedanib in patients with non-small cell lung cancer and interstitial lung disease;Journal of Thoracic Disease;2024-05

4. Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Respiratory Disease; Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease, and Tuberculosis;Cancers;2024-04-29

5. Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis;Annals of the American Thoracic Society;2024-04